This year’s top content in the Duchenne muscular dystrophy (DMD) space focused on a novel gene therapy approval, the high cost of care for this genetic disorder, and steps forward in other treatments.
DUBLIN--(BUSINESS WIRE)--The "Duchenne Muscular Dystrophy - Epidemiology Forecast to 2030" drug pipelines has been added to ResearchAndMarkets.com's offering. This report delivers an in-depth ...
This retrospective review compared appendicular lean mass (ALM) and ALM index among patients with Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD). Appendicular lean mass (ALM) and ...
A new 3D model shows that Duchenne gene therapy can repair muscle fibers but fails to shut down the signals that drive ...
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...
Wave Life Sciences has met its goal in a Duchenne muscular dystrophy (DMD) study, positioning it to talk to regulators about accelerated approval while continuing to track patients through to the ...
Early screening for Duchenne muscular dystrophy can help you get early treatments and referrals for your child to help prevent further loss of muscle tissue. Duchenne muscular dystrophy (DMD) is a ...
Duchenne muscular dystrophy (DMD) occurs as a result of genetic changes on the X chromosome. If someone has a gene change that can cause DMD, their children may inherit that change. DMD is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results